Table 1.

Clinical and genetic data available for patients in acute phase of atypical haemolytic uraemic syndrome (aHUS)

Patient no.	aHUS pathogenic change	Gender	Age at onset/time of study*	Treatment	Outcome
P1a†	C3: p.Arg161Trp 15,16	Male	1st episode: 6 years;2nd episode: 12 years	Plasma therapy	Remission
P2a	None	Female	7 years	Plasma therapy	Remission
P3a	Anti-CFH autoantibodies 19	Female	11 years	Plasma therapy, haemodialysis	Remission
P4a	MCP: p.Asp271_Ser272del 10	Male	1st episode: 4 years;2nd episode: 8 years	Plasma therapy	Remission
P5a†	None	Male	1st episode: 7 months;2nd episode: 2 years	Plasma therapy, eculizumab	Remission under eculizumab
P6a	None	Male	5 years	Plasma therapy, CVVHDF	Remission

^*Age at onset of the latest episode for these patients is equal to the age at the time of the study. First episodes of patients P1a, P4a and P5a resolved in (almost) complete remission without need of a renal transplantation.

^†Familial aHUS. CVVHDF = continuous veno-venous haemodiafiltration; CFH = complement factor H; MCP = membrane co-factor protein.